Randomized Controlled Trial
90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III...
J. Clin. Oncol. 2013 Jun 1; 31 (16): 1977-83.